Developmental toxicology studies of vancomycin hydrochloride administered intravenously to rats and rabbits.
Pregnant CD rats were given vancomycin intravenously in doses of 0, 40, 120, or 200 mg/kg on Gestation Days (GD) 6-15; pregnant New Zealand white rabbits were given 0, 40, 80, or 120 mg/kg intravenously on GD 6-18. Cesarean sections were performed on rats and rabbits on GD 20 and 28, respectively. In rats, maternal toxicity was indicated in the 120- and 200-mg/kg treatment groups by cortical tubular nephrosis. Maternal body weight gain and food consumption and fetal viability, weight, and morphology were not adversely affected by vancomycin. Maternal and developmental no observed adverse effect levels (NOAELs) in the rat were 40 and 200 mg/kg, respectively. In rabbits, maternal toxicity was indicated by cortical tubular nephrosis in the 80- and 120-mg/kg treatment groups; a single death and depression of body weight gain and food consumption occurred in the 120-mg/kg treatment group. Developmental toxicity was indicated by depression of fetal weight in the 120-mg/kg treatment group; fetal viability and morphology were not adversely affected by vancomycin. Maternal and developmental NOAELs in the rabbit were 40 and 80 mg/kg, respectively. Based on these data, vancomycin did not exhibit selective toxicity toward the developing rat or rabbit conceptus.
Byrd
R A
RA
Toxicology Research Laboratories, Lilly Research Laboratories, Division of Eli Lilly and Company, Greenfield, Indiana 46140.
Gries
C L
CL
Buening
M K
MK
D000818:Animals; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D005260:Female; D007275:Injections, Intravenous; D008098:Litter Size / Q000187:drug effects*; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D014640:Vancomycin / Q000008:administration & dosage / Q000633:toxicity*
D014640:Vancomycin